Oxygen-Saturated Blood Reduces Levels of Damaged Heart Tissue After Heart Attack
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Oxygen-Saturated Blood Reduces Levels of Damaged Heart Tissue After Heart Attack

MINNEAPOLIS, MN -- October 23, 2007 -- Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that an infusion of blood that is "supersaturated" with oxygen (SSO2) can reduce the amount of damaged heart muscle following a heart attack.

Despite successful reperfusion -- or restoration of blood flow to the heart with angioplasty following a heart attack -- there is often an area of infarction, or damaged heart muscle caused by the death of cells due to the interruption of oxygen carrying blood.

In the AMIHOT II trial, investigators led by Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center sought to determine the efficacy and safety of infusing SSO2 into the previously blocked artery after an angioplasty procedure.

"Among high-risk patients with acute anterior myocardial infarction (heart attack) undergoing successful angioplasty within 6 hours of symptom onset, infusion of SSO2 into the myocardial infarct territory results in a significant reduction in the size of the 'infarct zone,' the amount of damaged heart tissue," Stone said.

The AMIHOT II trial was conducted with 304 patients randomized at 20 sites in four countries.

Data from the study show that the size of the "infarct zone" was 6.5 percent lower in the patients treated with SSO2 than in control patients who did not receive the therapy.

In addition, at 30 days after the treatment, the rates of Major Adverse Cardiac Events (MACE) were statistically equivalent between the two groups.

SOURCE: Cardiovascular Research Foundation

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities